Impact Capital Partners LLC Acquires New Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Impact Capital Partners LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, Holdings Channel reports. The fund acquired 2,287 shares of the medical research company’s stock, valued at approximately $422,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Versant Capital Management Inc raised its position in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. raised its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. raised its position in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the last quarter. Tortoise Investment Management LLC raised its position in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after buying an additional 115 shares during the last quarter. Finally, ORG Wealth Partners LLC purchased a new position in Charles River Laboratories International during the 4th quarter worth approximately $56,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of the stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $167.03 on Friday. The company’s fifty day moving average price is $168.35 and its 200 day moving average price is $185.07. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The stock has a market capitalization of $8.54 billion, a P/E ratio of 1,113.55, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter in the previous year, the company posted $2.46 EPS. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CRL. Bank of America reduced their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. UBS Group reissued a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. JPMorgan Chase & Co. reduced their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $198.36.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).